Perspective of undergraduate health-care students on adverse drug reaction and pharmacovigilance

Perspective of undergraduate health-care students on adverse drug reaction and pharmacovigilance

Background: Pharmacovigilance (PV) is a crucial field of study everywhere. However, there is a serious knowledge gap regarding PV and adverse drug reactions (ADRs) reporting among health-care students. The aim of this study was to evaluate Libyan health-care students' understanding of PV and re...

Повний опис

Бібліографічні деталі
Автори:	Ahmed Atia, Eman Abdulwahed
Формат:	Стаття
Мова:	English
Опубліковано:	Wolters Kluwer Medknow Publications 2023-01-01
Серія:	Biomedical and Biotechnology Research Journal
Предмети:	adverse drug reactions healthcare students knowledge pharmacovigilance
Онлайн доступ:	http://www.bmbtrj.org/article.asp?issn=2588-9834;year=2023;volume=7;issue=4;spage=577;epage=581;aulast=Atia

Схожі ресурси

Knowledge, attitude, and practice among community pharmacists toward adverse drug reaction reporting and pharmacovigilance: A nationwide survey
за авторством: Tahani Alwidyan, та інші
Опубліковано: (2025-06-01)

Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study
за авторством: Alshareef H, та інші
Опубліковано: (2025-02-01)

Knowledge, Attitude, Practice, and Barriers of Adverse Drug Reaction Reporting Among Healthcare Professionals in Timor‐Leste: A Cross‐Sectional Survey
за авторством: Juanina daCosta, та інші
Опубліковано: (2025-01-01)

Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS
за авторством: Ye Xu, та інші
Опубліковано: (2024-10-01)

Knowledge, Attitude, and Practice Regarding Pharmacovigilance and Barriers to Reporting Adverse Drug Reactions Among the General Population in Saudi Arabia
за авторством: Alshehri H, та інші
Опубліковано: (2024-10-01)

Problematic aspects of participation of pharmacists in the system of pharmacovigilance in Russia
за авторством: E. N. Tkhoseva, та інші
Опубліковано: (2022-06-01)

IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE?
за авторством: Yu. V. Muravyev
Опубліковано: (2017-09-01)

Risks of oral anticoagulants: Analysis of adverse drug reactions reported to the Portuguese National Pharmacovigilance System
за авторством: Ana Sofia Martins, та інші
Опубліковано: (2024-10-01)

SIGNIFICANCE OF PHARMACOVIGILANCE AND ITS CLINICAL IMPLICATIONS
за авторством: Susanta Kumar Bandyopadhyay, та інші
Опубліковано: (2016-12-01)

Exploring the knowledge, perception, and practice of community pharmacists in Saudi Arabia toward pharmacovigilance and adverse drug reaction reporting. A nationwide survey
за авторством: Amani Khardali
Опубліковано: (2024-02-01)

Challenges and experiences in establishing a zonal pharmacovigilance centre at Bangabandhu Sheikh Mujib Medical University: A 10-month journey
за авторством: Elora Sharmin, та інші
Опубліковано: (2024-03-01)

Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals
за авторством: Josipa Bukić, та інші
Опубліковано: (2024-12-01)

Analysis of Data on Adverse Drug Reactions and Functional Flaws of the Pharmacovigilance System Associated with Self-Treatment with Antibiotics
за авторством: N. V. Verlan, та інші
Опубліковано: (2022-10-01)

Spontaneous adverse drug reactions reported in a thirteen-year pharmacovigilance program in a tertiary university hospital
за авторством: E. Montané, та інші
Опубліковано: (2024-12-01)

Current status and future prospects of pharmacovigilance in Pakistan
за авторством: Rabia Hussain, та інші
Опубліковано: (2019-12-01)

Evaluation of knowledge, attitude, and practice of adverse drug reactions reporting among doctors and nursing staff of a rural tertiary care teaching hospital of Maharashtra
за авторством: Satish E Bahekar, та інші
Опубліковано: (2018-01-01)

Prevalence of Cutaneous Adverse Drug Reactions According to Iraqi Pharmacovigilance Center; A retrospective study for 11 years (2010-2021)
за авторством: Ahmed Sami, та інші
Опубліковано: (2024-07-01)

Rational Organisation of Adverse Drug Reaction Monitoring
за авторством: L. V. Shukil, та інші
Опубліковано: (2022-10-01)

Pharmacovigilance: the evolution of drug safety monitoring
за авторством: Muhammad Akhtar Abbas Khan, та інші
Опубліковано: (2024-12-01)

Topical Issues of Drug Safety, Possibilities of Improving of Pharmacovigilance
за авторством: M. V. Zhuravleva, та інші
Опубліковано: (2019-09-01)

Knowledge, attitude, and practice study of pharmacovigilance in a dental teaching institute in Western India
за авторством: Rashmi Venkatesh, та інші
Опубліковано: (2024-10-01)

Levofloxacin: Analysis of Information on Adverse Reactions from Russian Spontaneous Report Database
за авторством: S. K. Zyryanov, та інші
Опубліковано: (2020-05-01)

Pharmacovigilance teaching and learning: a mixed cross-sectional analysis of the Portuguese public higher education system
за авторством: Margarida Perdigão, та інші
Опубліковано: (2024-01-01)

Knowledge and perception regarding adverse drug reactions among undergraduate medical students of Bihar, Eastern India
за авторством: Gurcharan S. Sidhu, та інші
Опубліковано: (2023-09-01)

Sins and Risks in Underreporting Suspected Adverse Drug Reactions
за авторством: Austin Due
Опубліковано: (2024-05-01)

Developing an electronic mobile reporting modality for pharmacovigilance in Namibia
за авторством: Babafunso A. Adenuga, та інші
Опубліковано: (2024-02-01)

Exploring healthcare professionals’ knowledge, attitude, and practices towards pharmacovigilance: a cross-sectional survey
за авторством: Rabia Hussain, та інші
Опубліковано: (2021-12-01)

COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
за авторством: G. I. Syraeva, та інші
Опубліковано: (2021-03-01)

Review of the monograph by Kolbin A. S., Zyryanov S. K., Belousov D. Yu. "Pharmacovigilance" 2025
за авторством: V. I. Petrov
Опубліковано: (2025-01-01)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases
за авторством: Menglin He, та інші
Опубліковано: (2024-02-01)

Adverse Reactions to Intravenous Immunoglobulin Therapy: An Analysis of the Russian National Pharmacovigilance Database
за авторством: A. V. Nechaev, та інші
Опубліковано: (2024-12-01)

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)
за авторством: Ruibo Li, та інші
Опубліковано: (2024-06-01)

Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study
за авторством: Jingying Wu, та інші
Опубліковано: (2024-09-01)

A prospective observational study to evaluate the prevalence of adverse drug reactions and its impact on quality of life in psychiatric patients at a tertiary care teaching hospital
за авторством: Megha Patel, та інші
Опубліковано: (2023-01-01)

Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
за авторством: Maoxia Fan, та інші
Опубліковано: (2024-07-01)

Assessment of knowledge, attitude, and practice of pharmacovigilance and materiovigilance among oral health practitioners in India
за авторством: Lucky Yadav, та інші
Опубліковано: (2024-01-01)

Retrospective analysis of adverse drug reactions leading to short-term emergency hospital readmission
за авторством: Sarah Banholzer, та інші
Опубліковано: (2021-01-01)

Sex and gender differences and pharmacovigilance: a knot still to be untied
за авторством: Liberata Sportiello, та інші
Опубліковано: (2024-04-01)

Pharmacovigilance Practices by Healthcare Providers in Oncology: A Cross-Sectional Study
за авторством: Hadeel Alkofide, та інші
Опубліковано: (2024-05-01)

The Adverse Drug Reactions Registered During the Postmarketing Period
за авторством: E. V. Shubnikova, та інші
Опубліковано: (2019-03-01)